it may be difficult to interpret the clinical relevance of the results. 3 In contrast, a global rating scale may be more useful for assessing the clinical relevance of patient change, and when used in addition to a symptom-specific rating scale, the aggregate outcomes may provide a comprehensive view of patient improvement or deterioration.
The Clinical Global Impressions (CGI) Scale 4 was designed to provide a clinician-rated view of a patient's global functioning before and after the initiation of study medication in clinical trials across psychiatric disease states. 5 Used in virtually all trials in psychiatric indications to suit regulatory requirements, the measure comprises 2 companion components, CGI-Severity (CGI-S) and -Improvement (CGI-I). At each study visit, an experienced clinician makes an informed judgement about the overall status of a patient including severity of illness and the impact of the illness on functioning; ratings take into account all available information, including patient history, symptoms, behaviour and psychosocial condition. in three 3-week randomised, double-blind, placebo-controlled studies in bipolar mania [6] [7] [8] and three 6-week randomised, double-blind, placebo-and active-controlled studies in schizophrenia. [9] [10] [11] In each of these studies, a significant difference vs placebo was seen in change from baseline on the primary efficacy measure (YMRS total score in the bipolar mania studies and PANSS total score in the schizophrenia studies); the CGI-S was the secondary efficacy measure in each study. In one additional study conducted in patients with schizophrenia (RGH-MD-03), 12 cariprazine did not separate from placebo on the primary efficacy parameter, change from baseline in PANSS total score.
To better characterise the clinical relevance of cariprazine treatment in improving disease severity, we conducted post hoc analyses based on CGI-S data from the positive randomised, controlled studies in bipolar disorder and schizophrenia. In practice, evaluating patient change using the global CGI-S rating in addition to assessing mean change on an efficacy rating scale may provide a clinically meaningful and statistically sound way of assessing of patient progress over time.
| METHODS

| Study design and patients
To assess CGI-S outcomes in patients with bipolar mania, data were pooled from 3 positive phase II/III, randomised, 3-week double-blind placebo-controlled studies. RGH-MD-31 (NCT00488618) 7 and RGH-MD-32 (NCT01058096) 8 were flexible-dose studies with cariprazine 3-12 mg/d; RGH-MD-33 (NCT01058668) 6 was a fixed/flexible-dose study with 2 cariprazine treatment arms (3-6 mg/d or 6-12 mg/d).
To assess CGI-S outcomes in patients with schizophrenia, data were pooled from the 3 positive phase II/III, randomised, 6-week 
What's new
In post hoc analyses, greater improvements in CGI-Severity (CGI-S) measures were seen in cariprazine-vs placebotreated patients with bipolar disorder or schizophrenia.
Clinically relevant shifts to less severe disease were also apparent in both disease states. This suggests that cariprazine was associated with clinically meaningful improvement and clinicians may be able to assess improvement based on clinical judgement as well as rating scale change.
schizophrenia, respectively; various other psychiatric conditions, substance abuse and suicide risk were exclusionary. Concurrent medical conditions that could interfere with the conduct of the study, confound the interpretation of results or endanger the patient's well-being were additional criteria for exclusion. Drugs with psychotropic activity were prohibited except for lorazepam (for agitation, hostility and restlessness), eszopiclone, zolpidem, chloral hydrate or zaleplon (for insomnia), and diphenhydramine, benztropine or propranolol (for extrapyramidal symptoms).
| Post hoc analyses
Post hoc analyses were conducted on patient data collected from the CGI-S administered during the constituent studies; data were pooled by disease state. Category shift analyses were conducted to determine the percentage of cariprazine-and placebo-treated patients who shifted from a more severe illness category at baseline to a less severe category at the end of treatment. The shift categories for analysis were defined as "severely or extremely ill (CGI-S ≥ 6) to mildly ill or better (CGI-S ≤ 3)"; "markedly ill or worse (CGI-S ≥ 5) to borderline ill/normal (CGI-S ≤ 2)"; and "moderately ill or worse (CGI-S ≥ 4) to borderline ill/normal (CGI-S ≤ 2)." Patients were categorised by baseline CGI-S score;
between-group comparison of categorical improvement at end-point was analysed using a logistic regression model with study, treatment group and corresponding baseline value as explanatory variables; missing data were imputed using the last observation carried forward (LOCF) approach. Odds ratios (ORs), 95% confidence intervals (CIs) and P values were calculated for each comparison of cariprazine vs placebo; P values were not adjusted for multiple comparisons and all statistical tests were 2-sided at the 5% significance level.
Analyses were also conducted to determine if the CGI-S shift to less severe illness categories correlated with mean changes from baseline in YMRS and PANSS total score for patients with bipolar mania and schizophrenia, respectively. Pearson's correlation coefficients were determined for the relationship between categorical shift and change in rating scale total score using a generalised linear mixed model with CGI-S shift and change from baseline in YMRS or PANSS total score as responses, and study, treatment and the corresponding baseline value as a covariate in the joint model.
A post hoc sensitivity analysis was conducted to assess the robustness of the CGI-S analyses in patients with schizophrenia. This analysis included data from RGH-MD-03, 12 the negative exploratory cariprazine study in schizophrenia.
| RESULTS
| Patient disposition and baseline characteristics
Data Demographic and baseline characteristics of the pooled populations by CGI-S severity baseline score are presented in Table 1 .
In both disease states, the majority of patients were markedly ill (CGI-S = 5) at baseline; age, gender and disease characteristics were generally similar among baseline severity subgroups. Race distribution differed slightly across severity subgroups in both disease states. Mean age at onset and duration of illness were similar across baseline severity subgroups; mean number of hospitalisations was higher in the most severe baseline subgroup in both disease states.
| CGI-S score distribution
At baseline, the majority of patients were markedly (bipolar mania = 52%; schizophrenia = 60%) or moderately ill (bipolar mania = 38%; schizophrenia = 30%); fewer patients were severely or extremely ill at baseline (bipolar mania = 9%; schizophrenia = 11%).
Only 4 patients with bipolar disorder and no patients with schizophrenia were mildly ill or better at baseline.
| Bipolar mania
Change in the distribution of CGI-S scores from baseline to the end of treatment showed that a higher percentage of cariprazine-vs placebotreated patients improved to a CGI-S score corresponding to less severe illness at end-point, regardless of the baseline severity score 
| Schizophrenia
| Categorical CGI-S improvement
In both disease states, a higher percentage of cariprazine-treated patients than placebo-treated patients shifted to a less severe category of illness in each shift analysis ( Figure 3A and B).
| Bipolar mania
In patients with bipolar mania, the odds of shifting to a less severe illness category were of similar magnitude in favour of 
| Schizophrenia
The percentage of patients in the extremely or severely ill baseline disease category who shifted to a less severe disease category was considerably larger than the percentage of patients who shifted in the less severe baseline categories. In the extremely or severely ill (CGI-S ≥ 6) baseline disease category, 47 (42%) cariprazine patients and 9 (18%) placebo patients shifted to the mildly ill or better category were again statistically significant (P = .0494).
F I G U R E 2 Schizophrenia: distribution of CGI-S scores at the end of treatment in patients with (A) severe/extreme, (B) marked, or (C) moderate baseline illness severity. A higher percentage of cariprazine-than placebo-treated patients improved to a CGI-S score corresponding to less severe illness at end-point in each baseline illness category. Distribution of CGI-S scores by severity: normal = 1; borderline ill = 2; mildly ill = 3, moderately ill = 4; markedly ill = 5; severely/extremely ill ≥ 6
(A) (B) (C)
A sensitivity analysis that included the results of the negative exploratory cariprazine study in schizophrenia was conducted (RGH-MD-03). 12 The primary findings of our post hoc analysis were supported by the category shift from severely or extremely ill at baseline to mildly ill or better at the end of double-blind treatment; the odds of shifting remained statistically significant for cariprazine vs placebo 
| Categorical CGI-S improvement and symptom severity
The least squares mean differences (LSMDs) and associated 95% CIs in change from YMRS total score baseline for patients with bipolar mania were statistically significant in favour of cariprazine vs placebo in the extremely or severely ill (CGI-S ≥ 6) category (−7. severe CGI-S illness category were small to moderate in most severity categories ( Table 2) . Correlations between category shift and mean rating scale change were larger for patients with the most severe illness at baseline and in patients with bipolar mania relative to patients with schizophrenia. Cariprazine-and placebo-treated patients with bipolar disorder and schizophrenia who shifted to a less severe CGI-S category had considerably larger changes from baseline in YMRS and PANSS total scores, respectively.
| DISCUSSION
The efficacy of cariprazine in patients with mania associated with bi- CAR, cariprazine; CGI-S, Clinical Global Impressions-Severity; PANSS, Positive and Negative Syndrome Scale; PBO, placebo; YMRS, Young Mania Rating Scale.
a YMRS score < 12; remission has been further operationalised as a CGI-Bipolar Disorder Scale severity score ≤ 2 (borderline ill) for both mania and depression. 14 In our post hoc category shift analyses, significantly more cariprazine-treated patients than placebo-treated patients with bipolar disorder shifted to borderline ill (CGI-S = 2) or normal (CGI-S = 1), which would suggest that these patients reached symptomatic remission with treatment. Residual symptoms after resolution of a major affective episode in patients with bipolar disorder are associated with significant risk of rapid relapse or recurrence. 15 As such, attaining near symptom-free status for patients with bipolar mania suggests a stable recovery, with greater potential for regaining and retaining premorbid functional status.
The Remission in Schizophrenia Working Group (RSWG) has proposed PANSS-based remission criteria for schizophrenia that has cross-scale correspondence and a relationship with DSM-IV criteria. 16 In a study investigating the reliability of CGI-S for evaluating remission, a CGI-Schizophrenia Scale severity score ≤ 3 (mildly ill) corresponded to RSWG remission criteria. 17 In our post hoc category shift analyses, significantly more cariprazine-than placebo-treated patients with schizophrenia shifted to a category with end-point CGI-S scores ≤ 3 regardless of the level of baseline disease severity. This would suggest that more cariprazine-than placebo-treated patients attained remission of symptoms corresponding to RSWG criteria. Although higher percentages of patients with bipolar disorder met the relevant remission threshold than did patients with schizophrenia, the category shift appears to an operative indication of remission in patients with either disorder.
Across baseline levels of disease severity in both indications, cariprazine-treated patients had larger mean changes in YMRS or PANSS total score than placebo-treated patients; cariprazine-treated patients with schizophrenia had mean PANSS total score change that exceeded the 15-point reduction threshold that correlates with one level of CGI-S improvement. 18 Placebo-and cariprazine-treated patients who shifted to a less severe CGI-S category had considerably greater mean rating scale change than patients who did not shift, suggesting that clinicians may be able to assess improvement based on clinical judgement as well as rating scale change. For both bipolar disorder and schizophrenia, the statistical analysis of the relationship between categorical improvement and rating scale score change yielded the largest correlation coefficient in the most severe baseline illness category where room for improvement was the greatest; patients in this CGI-S baseline category who did not shift during treatment had minimal rating scale improvement indicating that treatment provided less benefit for them. Although CGI-S category shifts correlated well with improvements in symptom scales, the moderate magnitude of the correlations suggests that each of these outcomes may be measuring additional factors that are complementary to the other outcome.
In the constituent studies, scores at end-point on the CGI-I, the companion component of the CGI-S, supported our post hoc observations of improvement in global disease severity. Across each cariprazine dose that was evaluated, mean CGI-I scores at end-point were between much improved (CGI-I = 2) and minimally improved (CGI-I = 3) and significantly different than placebo in the bipolar disorder studies at week 3 (P < .001 each) [6] [7] [8] and in the schizophrenia studies at week 6 (P < .01 each). [9] [10] [11] Additionally, in a previous post hoc pooled analysis of data from the constituent bipolar disorder studies, the rate of CGI-I response (score ≤ 2, much/very much improved) was significantly greater for cariprazine-(64%) vs placebotreated (42%) patients (P < .0001), 19 providing further support for our analyses. Improvements in both CGI-S and CGI-I suggest that global impressions were consistent across the components of the CGI Scale and cariprazine-treated patients with bipolar mania or schizophrenia experienced significantly greater global improvement than placebotreated patients did.
The CGI has been validated as a clinical outcome measure for routine use in inpatient psychiatric settings in patients with a variety of diagnoses. 20 The advantages of the scale include its established utility in psychiatric research, sensitivity to change, easy administration, usefulness across diagnostic subgroups and reliability when administered by a skilled clinician. 20 Given these properties, the CGI can be readily adapted for use in clinical practice, where it can help a clinician consistently track interventions over the course of care. 5 However, limitations associated with the CGI Scale have also been cited, including its lack of consistency, unreliability and being too general to provide meaningful information about clinical status or treatment response. 21 Scoring is dependent on the clinical judgement of the rater and there are no universally established scoring guidelines for the 7 anchor points; as such, variability in scoring could occur. 5 In spite of these limitations, however, the CGI-S has been shown to be well correlated with other scales across a range of psychiatric indications. 5 Collective experiences suggest that using a global impression of illness severity in addition to mean change on an efficacy rating scale may provide an integrated approach for assessing clinically meaningful patient improvement in research or clinical practice settings.
Although these analyses were post hoc and have inherent limitations, they allowed for the evaluation of CGI-S data from large numbers of patients with bipolar I disorder or schizophrenia. As is typical in post hoc evaluations, P values were not adjusted for multiple comparisons, which may have allowed random chance to play a role in determining statistically significant differences. The short duration of the constituent studies further limits interpretation of these findings. Stringent inclusion and exclusion criteria limit the ability to generalise results to other populations of patients with bipolar I disorder or schizophrenia; of note, patients with bipolar II disorder, rapid cycling, significant depressive symptoms and treatment-resistant schizophrenia were excluded from participation. As previously discussed, the CGI-S has psychometric limitations including lack of standard scoring guidelines; these post hoc analyses were adjusted for study site to help lessen the potential for inter-rater variability in CGI-S scoring. From a statistical perspective, correlating implicit CGI-S ratings with explicitly calculated efficacy scale mean changes may be problematic, but finding a correlation between category shifts and rating scale improvement helped to substantiate our CGI-S findings nonetheless.
Statistical significance is not the same as clinical relevance. While small numerical differences on a rating scale may produce statistically significant change in a large sample size, a change is only clinically mean- 
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